A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

This study tests a combination of two new bispecific antibody drugs — SI-B001 and SI-B003 — along with platinum-based chemotherapy as a first-line treatment for people with recurrent or metastatic squamous cell carcinoma of the head and neck (mouth, throat, and nearby areas). **You may be eligible if...** - You are 18–75 years old with recurrent or metastatic head and neck squamous cell carcinoma - You have not received prior chemotherapy for metastatic or recurrent disease - You have at least one measurable tumor on scans - You are in good health (ECOG ≤ 1) with adequate organ function - You have a life expectancy of at least 3 months **You may NOT be eligible if...** - Your cancer is from the nasopharynx, salivary gland, paranasal sinus, skin, or unknown primary site - You have active brain metastases - You received radiotherapy or another clinical trial treatment within 4 weeks before starting - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.